| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/20-1/50 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/20-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Aspartate transcarbamylase; CAD protein; CAD trifunctional protein; Carbamoyl phosphate synthetase 2; CPSase ATCase DHOase; Dihydroorotase;;CAD |
| WB Predicted band size | Calculated MW: 243 kDa ; Observed MW: 260 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human CAD |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于CAD抗体(冷凝集素病相关抗体)的3篇代表性文献信息，供参考：
1. **文献名称**：Cold agglutinin disease: current challenges and future prospects
**作者**：Barcellini W, et al.
**摘要**：综述冷凝集素病的病理机制，重点解析CAD抗体(多为IgM型)如何通过结合红细胞表面抗原引发补体介导的溶血。探讨传统治疗(如利妥昔单抗)及新型补体抑制剂的疗效。
2. **文献名称**：Rituximab plus bendamustine for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial
**作者**：Berentsen S, et al.
**摘要**：临床试验评估利妥昔单抗联合苯达莫司汀治疗难治性CAD的效果，发现联合疗法显著降低抗体滴度并改善溶血指标，总有效率超过80%。
3. **文献名称**：Inhibition of complement C1s with sutimlimab in patients with cold agglutinin disease (CAD): results from the phase 3 CARDINAL study
**作者**：Jäger U, et al.
**摘要**：III期临床试验证实补体C1s抑制剂Sutimlimab可快速阻断CAD抗体介导的补体活化，73%患者实现血红蛋白水平持续改善，提示靶向补体通路的新型治疗潜力。
注：上述文献均为真实研究，具体发表年份及期刊可通过PubMed等平台检索。如需扩展，可补充冷凝集素检测技术相关指南(如《Blood》发表的实验室诊断共识)。
CAD antibodies, primarily associated with autoimmune liver diseases, target specific intracellular enzymes involved in metabolic pathways. The term "CAD" refers to the trifunctional carbamoyl-phosphate synthetase 2. aspartate transcarbamylase, and dihydroorotase (CAD) protein, a key enzyme in pyrimidine biosynthesis. Initially identified in autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC), these autoantibodies are detected via indirect immunofluorescence or immunoblotting.
CAD antibodies are part of a broader spectrum of antinuclear antibodies (ANA) but exhibit distinct cytoplasmic staining patterns. Their presence correlates with specific clinical subtypes, particularly in AIH type 1. where they may coexist with anti-SMA or anti-LKM1 antibodies. Though their exact pathogenic role remains unclear, CAD antibodies serve as diagnostic markers, aiding in differentiating autoimmune liver disorders from other hepatobiliary conditions.
Recent studies suggest CAD antibodies may also appear in systemic autoimmune diseases like rheumatoid arthritis or Sjögren's syndrome, hinting at shared molecular mechanisms. Research continues to explore their prognostic value and relationship to disease activity. Despite low prevalence (5–15% in AIH), their identification enhances serological profiling, supporting personalized treatment approaches in autoimmune hepatology.
×
